Ocugen Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Good afternoon and thanks for joining us to have a conversation with Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. Ocugen is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that employ health and offer hope for patients across the globe.
The company's lead program in gene therapies, OCU400, is currently in the clinic. Additionally, the company has also entered into a development and commercial agreement with an Indian pharma, Bharat Biotech, to commercialize their whole-variant inactivated COVID-19 vaccine called Covaxin.
Covaxin currently has been approved under an EUA in India. The company has regulatory applications for marketing Covaxin in the US, Canada, and Mexico. Additionally, Ocugen recently initiated a clinical program with NeoCart that currently has RMAT designation. So to learn about the deep pipeline of Ocugen, let's get started with Shankar.
Shankar, glad to see you, and I
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |